Biologics for the treatment of Juvenile Idiopathic Arthritis

Dimitri Poddighe, Micol Romano, Maurizio Gattinara, Valeria Gerloni

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - May 21 2018

Fingerprint

Juvenile Arthritis
Biological Products
Pharmacodynamics
Pharmaceutical Preparations
Pharmacokinetics
Lymphocytes
Immune system
Lymphocyte Activation
Interleukin-1
Immune System
Interleukin-6
Chronic Disease
Therapeutics
Chemical activation
Availability

Cite this

Biologics for the treatment of Juvenile Idiopathic Arthritis. / Poddighe, Dimitri; Romano, Micol; Gattinara, Maurizio; Gerloni, Valeria.

In: Current Medicinal Chemistry, 21.05.2018.

Research output: Contribution to journalArticle

Poddighe, Dimitri ; Romano, Micol ; Gattinara, Maurizio ; Gerloni, Valeria. / Biologics for the treatment of Juvenile Idiopathic Arthritis. In: Current Medicinal Chemistry. 2018.
@article{607f2b5f11834845b2b74b12e1eea24e,
title = "Biologics for the treatment of Juvenile Idiopathic Arthritis",
abstract = "Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.",
author = "Dimitri Poddighe and Micol Romano and Maurizio Gattinara and Valeria Gerloni",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "5",
day = "21",
doi = "10.2174/0929867325666180522085716",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Biologics for the treatment of Juvenile Idiopathic Arthritis

AU - Poddighe, Dimitri

AU - Romano, Micol

AU - Gattinara, Maurizio

AU - Gerloni, Valeria

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/5/21

Y1 - 2018/5/21

N2 - Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

AB - Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

U2 - 10.2174/0929867325666180522085716

DO - 10.2174/0929867325666180522085716

M3 - Article

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -